EUVIMEDEUVIMED entdecken
Open Access

Noninvasive Identification of Isocitrate Dehydrogenase 1/2 Mutation in Brainstem Gliomas

Marina Kushnirsky iD, Andrew L Lin iD, Tejus Bale iD, Nelson S Moss iD, Marc Rosenblum iD, Sameer Farouk Sait, Lauren R Schaff iD, Igor T Gavrilovic, Elena Pentsova, Christian Grommes iD, Alicia Meng, Brandon Imber iD und 8 weitere

JCO Precision Oncology · 2026

DOI: 10.1200/po-25-00859 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JCO Precision Oncology, 2026. Verfasst von Marina Kushnirsky und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY. Hauptthemen laut MEDLINE: Isocitrate Dehydrogenase, Mutation, Glioma, Brain Stem Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE A subset of brainstem gliomas harbor an isocitrate dehydrogenase 1/2 ( IDH1/2 ) mutation, which has important prognostic and treatment implications. We evaluated the radiographic features and the sensitivity of magnetic resonance spectroscopy (MRS) and cerebrospinal fluid cell-free DNA (CSF cfDNA) sequencing at detecting IDH1/2 mutations in a cohort of these tumors. METHODS We identified IDH-mutant brainstem gliomas by retrospective chart review. IDH1/2 mutation was established by biopsy, CSF cfDNA sequencing, and/or the presence of a 2-hydroxyglutarate (2HG) peak by 3-Tesla MRS. RESULTS Twenty-one patients with IDH-mutant brainstem gliomas were identified, 57% male with a median age of 26 (6-59) years. All tumors involved the pons and/or abutted the brachium pontis. Although 18 (86%) of 21 were nonenhancing, only one of 21 demonstrated T2-FLAIR mismatch. An IDH1/2 mutation was identified by biopsy in 17 and by CSF cfDNA sequencing in three; in the final patient, an IDH1/2 mutation was inferred by the presence of a 2HG peak. The sensitivity of MRS at identifying 2HG in patients with confirmed IDH1/2 mutations was 64.3% (95% CI, 35.1 to 87.2), which increased to 85.7% (95% CI, 42.1 to 99.6) when the study was performed before treatment. The 2HG peak was absent in all four patients with a repeat MRS after completion of radiation. IDH1/2 mutation was identified in four of seven patients who underwent sequencing of CSF cfDNA. In this cohort, median progression-free survival and overall survival were 57.6 and 90.4 months, respectively. An objective response to radiotherapy was observed in 76%. CONCLUSION IDH-mutant brainstem gliomas have a characteristic clinical and radiographic phenotype. MRS is more sensitive than CSF cfDNA sequencing for noninvasively identifying the presence of an IDH1/2 mutation when performed before radiotherapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Isocitrate DehydrogenaseMutationGliomaBrain Stem NeoplasmsHumansMaleRetrospective StudiesFemaleMiddle AgedAdultAdolescentChildYoung AdultMagnetic Resonance Spectroscopy

Substanzen

Isocitrate DehydrogenaseIDH2 protein, humanIDH1 protein, human

Autor:innen und Institutionen

  • Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY.
  • Department of Neurosurgery, Memorial Sloan Kettering Cancer Center, New York, NY.
  • Weill Cornell Medical College, New York, NY.
  • Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY.
  • Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY.
  • Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY.

ORCID-Profile: Marina Kushnirsky, Andrew L Lin, Tejus Bale, Nelson S Moss, Marc Rosenblum, Lauren R Schaff, Christian Grommes, Brandon Imber, Kenny Kwok Hei Yu, Rachna Malani, Matthias A Karajannis, Ingo Mellinghoff, Sunitha Thakur

Förderung

  • NCI NIH HHS

Zitieren

APA

Kushnirsky, M., Lin, A. L., Bale, T., Moss, N. S., Rosenblum, M., Sait, S. F., Schaff, L. R., Gavrilovic, I. T., Pentsova, E., Grommes, C., Meng, A., Imber, B., Tabar, V., Yu, K. K. H., Miller, A., Malani, R., Karajannis, M. A., Mellinghoff, I., Young, R. J., & Thakur, S. (2026). Noninvasive Identification of Isocitrate Dehydrogenase 1/2 Mutation in Brainstem Gliomas. JCO Precision Oncology. https://doi.org/10.1200/po-25-00859

Vancouver

Kushnirsky M, Lin AL, Bale T, Moss NS, Rosenblum M, Sait SF, et al. Noninvasive Identification of Isocitrate Dehydrogenase 1/2 Mutation in Brainstem Gliomas. JCO Precision Oncology. 2026. doi:10.1200/po-25-00859

BibTeX
@article{Kushnirsky2026,
  author = {Kushnirsky, Marina and Lin, Andrew L and Bale, Tejus and Moss, Nelson S and Rosenblum, Marc and Sait, Sameer Farouk and Schaff, Lauren R and Gavrilovic, Igor T and Pentsova, Elena and Grommes, Christian and Meng, Alicia and Imber, Brandon and Tabar, Viviane and Yu, Kenny Kwok Hei and Miller, Alexandra and Malani, Rachna and Karajannis, Matthias A and Mellinghoff, Ingo and Young, Robert J and Thakur, Sunitha},
  title = {Noninvasive Identification of Isocitrate Dehydrogenase 1/2 Mutation in Brainstem Gliomas},
  journal = {JCO Precision Oncology},
  year = {2026},
  doi = {10.1200/po-25-00859}
}
Kostenlos starten →